Revision: Dec. 29, 2015, midnight
\t \t\tHB 1680-FN - AS INTRODUCED
2016 SESSION
\t16-2393
\t01/09
HOUSE BILL\t1680-FN
AN ACT\textending the suspension of prior authorization requirements for a community mental health program on drugs used to treat mental illness.
SPONSORS:\tRep. Sherman, Rock. 24; Rep. Snow, Hills. 42; Sen. Fuller Clark, Dist 21
COMMITTEE:\tHealth, Human Services and Elderly Affairs
-----------------------------------------------------------------
ANALYSIS
\tThis bill extends the suspension of prior authorization requirement for a community mental health program on drugs used to treat mental illness.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation:\tMatter added to current law appears in bold italics.
\t\tMatter removed from current law appears [in brackets and struckthrough.]
\t\tMatter which is either (a) all new or (b) repealed and reenacted appears in regular type.
\t16-2393
\t01/09
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Sixteen
AN ACT\textending the suspension of prior authorization requirements for a community mental health program on drugs used to treat mental illness.
Be it Enacted by the Senate and House of Representatives in General Court convened:
\t1 Department of Health and Human Services; Prior Authorization for Certain Prescription Drugs; Oversight Committee on Health and Human Services; Reports. Amend 2015, 199:2 to read as follows:
\t199:2 Department of Health and Human Services; Prior Authorization for Certain Prescription Drugs; Oversight Committee on Health and Human Services; Reports Required. The department of health and human services in collaboration with the managed care organizations and community mental health programs shall provide an initial report on or before July 31, 2015 to the oversight committee on health and human services, established in RSA 126-A:13. The report shall focus on a detailed clinical review of policies and procedures that govern the administration of the pharmacy benefit. The report shall identify the necessary revisions required to promote the behavioral health and well being of New Hampshire’s citizens being served under Medicaid managed care. Progress reports shall be provided by the department to the oversight committee on or before August 31, 2015 [and], September 30, 2015, November 1, 2015, and June 30, 2016 respectively. A final report including findings and any recommendations for proposed legislation shall be provided by the department to the oversight committee on or before November 1, [2015] 2016.
\t2 Prior Authorization for Certain Prescription Drugs; Suspension; Repeal. Amend 2015, 199:4, I to read as follows:
\t\tI. Section 3 of this act shall take effect June 30, [2016] 2017.
\t3 Effective Date. This act shall take effect upon its passage.
\t\t\t\t\t\t\t\t\t\t\t16-2393
\t\t\t\t\t\t\t\t\t\t\t11/2/15
HB 1680-FN- FISCAL NOTE
AN ACT\textending the suspension of prior authorization requirements for a community mental health program on drugs used to treat mental illness.
FISCAL IMPACT:
The Department of Health and Human Services states this bill, as introduced, will have an indeterminable impact on state restricted revenue and state expenditures in FY 2017 only. There will be no impact on county or local revenue and expenditures.
METHODOLOGY:
The Department of Health and Human Service states this bill extends the suspension of prior authorization requirements that relate to the ability of community mental health programs to prescribe medication used to treat severe mental illness. Currentlly, RSA 126-A:5, XIX(e) requires managed care organizations (MCO) providing prescription drug benefits to Medicaid recipients to suspend prior authorization requirements for medication prescribed at a community mental health center and used to treat severe mental illness such as schizophrenia, depression, or bipolar disorder. Absent legislative action, this provision will be repealed effective June 30, 2016. By extending the repeal date, this bill continues the suspension of prior authorization requirements until June 30, 2017. In addition, the bill extends for an additional year, until November 1, 2016, the deadline for the Department, MCOs, and community mental health programs to provide a report on administration of the pharmacy benefit under the Medicaid managed care program. The Department states the fiscal impact of the bill is indeterminable, but may result in either lost cost savings or additional costs that might be incurred as a result of the continuation of the prohibition on prior authorization requirements. Any fiscal impact would occur in FY 2017 only.